Investors

investor people image

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Osiris Therapeutics Launches Prestige™ Lyotechnology, a Novel Method for Ambient Storage of Living Cells and Tissues
COLUMBIA, Md., March 30, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that it has developed cutting edge technology enabling the preservation of living cells and tissues
View HTML
Toggle Summary Osiris Therapeutics, Inc. Completes Restatement of 2014 Financial Statements
COLUMBIA, Md., March 27, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced that it completed the restatement of its 2014 financial statements by filing an amended Annual Report on
View HTML
Toggle Summary Osiris Receives Notice of Delisting from NASDAQ
COLUMBIA, Md., March 10, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the "Company") announced today that the Company received a letter from the NASDAQ Stock Market ("NASDAQ") stating that trading of the Company's common stock will be suspended at the opening of business on Tuesday, March 14, 2017. The letter also states that
View HTML
Toggle Summary Osiris Appoints Uwe Sommer and Thomas Knapp to its Board of Directors
COLUMBIA, Md. , Feb. 10, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) is pleased to announce that its Board of Directors, at a Board Meeting on February 7th, 2017, confirmed the appointment of Messrs. Uwe Sommer and Thomas J. Knapp as Directors, upon recommendation of the Nominating Committee, and each will stand for election
View HTML
Toggle Summary Osiris Therapeutics announced a Comparative Effectiveness Study on the Use of Two Human Placental Membranes in Wound Management is Available Electronically in a Peer-Reviewed Journal
COLUMBIA, Md., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced today that the study "A Comparative Outcomes Analysis Evaluating Clinical Effectiveness in Two Different Human Placental Membrane Products for Wound Management"  has been published in the peer-reviewed journal Wound Repair and Regeneration and is
View HTML
Toggle Summary Osiris Therapeutics Announces Scientific Manuscript Reporting Antimicrobial Properties of Cryopreserved Viable Amnion is Available Electronically in Peer-Reviewed Journal
COLUMBIA, Md., Jan. 13, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), announced today that  a new peer-reviewed manuscript "Human cryopreserved viable amniotic membrane inhibits the growth of bacteria associated with chronic wounds" (Mao et al.) has been published in the Journal of Diabetic Foot Complications and available
View HTML
Toggle Summary Osiris Provides Update Regarding NASDAQ Listing Matters View HTML
Toggle Summary Peer-reviewed Publication on the use of Grafix® in High-Risk Peripheral Arterial Disease Patients with Treatment Refractory Ulcerations Demonstrating Durable Wound Closure View HTML
Toggle Summary Osiris Provides Update Regarding NASDAQ Listing Matters View HTML
Toggle Summary Osiris Therapeutics, Inc. Reports Preliminary 2014 and 2015 Revenue and Anticipated 2016 Revenue View HTML